These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 23473590)
1. Lucinactant for the prevention of respiratory distress syndrome in premature infants. Jordan BK; Donn SM Expert Rev Clin Pharmacol; 2013 Mar; 6(2):115-21. PubMed ID: 23473590 [TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R; Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381 [TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Moya FR; Gadzinowski J; Bancalari E; Salinas V; Kopelman B; Bancalari A; Kornacka MK; Merritt TA; Segal R; Schaber CJ; Tsai H; Massaro J; d'Agostino R; Pediatrics; 2005 Apr; 115(4):1018-29. PubMed ID: 15805380 [TBL] [Abstract][Full Text] [Related]
4. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Moya F; Sinha S; Gadzinowski J; D'Agostino R; Segal R; Guardia C; Mazela J; Liu G; Pediatrics; 2007 Jun; 119(6):e1361-70. PubMed ID: 17533176 [TBL] [Abstract][Full Text] [Related]
6. Lucinactant for the treatment of respiratory distress syndrome in neonates. Piehl E; Fernandez-Bustamante A Drugs Today (Barc); 2012 Sep; 48(9):587-93. PubMed ID: 23032799 [TBL] [Abstract][Full Text] [Related]
7. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Pfister RH; Soll RF; Wiswell T Cochrane Database Syst Rev; 2007 Jul; (3):CD006069. PubMed ID: 17636826 [TBL] [Abstract][Full Text] [Related]
8. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Pfister RH; Soll RF; Wiswell T Cochrane Database Syst Rev; 2007 Oct; (4):CD006069. PubMed ID: 17943881 [TBL] [Abstract][Full Text] [Related]
9. Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome. Gastiasoro-Cuesta E; Alvarez-Diaz FJ; Rey-Santano C; Arnaiz-Renedo A; Loureiro-Gonzalez B; Valls-i-Soler A Pediatrics; 2006 Feb; 117(2):295-303. PubMed ID: 16452346 [TBL] [Abstract][Full Text] [Related]
10. Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome. Donn SM Expert Opin Investig Drugs; 2005 Mar; 14(3):329-34. PubMed ID: 15833063 [TBL] [Abstract][Full Text] [Related]
12. Lucinactant: in neonatal respiratory distress syndrome. Moen MD; Perry CM; Wellington K Treat Respir Med; 2005; 4(2):139-45; discussion 146-7. PubMed ID: 15813666 [TBL] [Abstract][Full Text] [Related]
13. Aerosolized lucinactant: a potential alternative to intratracheal surfactant replacement therapy. Donn SM; Sinha SK Expert Opin Pharmacother; 2008 Feb; 9(3):475-8. PubMed ID: 18220497 [TBL] [Abstract][Full Text] [Related]
14. Pulmonary distribution of lucinactant and poractant alfa and their peridosing hemodynamic effects in a preterm lamb model of respiratory distress syndrome. Terry MH; Merritt TA; Harding B; Schroeder H; Merrill-Henry J; Mazela J; Gregory TJ; Segal R; Power GG; Blood AB Pediatr Res; 2010 Sep; 68(3):193-8. PubMed ID: 20531255 [TBL] [Abstract][Full Text] [Related]
15. Lucinactant approved for respiratory distress syndrome. Traynor K Am J Health Syst Pharm; 2012 Apr; 69(8):628. PubMed ID: 22472860 [No Abstract] [Full Text] [Related]
16. A pilot, randomized, controlled clinical trial of lucinactant, a peptide-containing synthetic surfactant, in infants with acute hypoxemic respiratory failure. Thomas NJ; Guardia CG; Moya FR; Cheifetz IM; Markovitz B; Cruces P; Barton P; Segal R; Simmons P; Randolph AG; Pediatr Crit Care Med; 2012 Nov; 13(6):646-53. PubMed ID: 22791092 [TBL] [Abstract][Full Text] [Related]
17. Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases. Mazela J; Merritt TA; Gadzinowski J; Sinha S Acta Paediatr; 2006 Sep; 95(9):1036-48. PubMed ID: 16938747 [TBL] [Abstract][Full Text] [Related]
18. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Ardell S; Pfister RH; Soll R Cochrane Database Syst Rev; 2015 May; (5):CD000144. PubMed ID: 26009996 [TBL] [Abstract][Full Text] [Related]